开拓创新·关爱人生
万邦德制药集团—专业从事现代中药、化学原料药及其制剂研发、生产和销售的高新技术企业
R&D
All categories
Medical Research Enterprise Alliance
In order to create a pharmaceutical industry system with strong core competitiveness and change the situation that some key pharmaceutical technologies and core products are controlled by others, since 2017, Wanbangde Pharmaceutical Group has joined hands with China Pharmaceutical University, Zhejiang University, China Academy of Chinese Medical Sciences, Second Military Medical University, Experts and professors from more than ten medical research institutions, including Beijing Anzhen Hospital, West China Hospital of Sichuan University, and the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, led by Academician Wang Guangji to establish the first domestic collaborative alliance of medical research enterprises for pharmaceutical products -Ginkgo biloba The Collaborative Innovation Alliance of Dripping Pill Medical Research Enterprises，Focusing on the in-depth research of the company's flagship product, Ginkgo biloba dripping pills, and achieved good results: published21scientific papers and paper impact factors; obtained11patents; included in14clinical guidelines, expert consensus and the National Health Commission Guided the compilation of "Interpretation of Clinical Pathways", etc.; the product has won12honors.
China Pharmaceutical University | Joint R&D Center
Cooperation time
September 2015 - present
Project Description
February 2017
Signed an agreement to jointly build the“China Pharmaceutical University-Wanbangde Drug Research and Development Center”with a total capital scale of more than 10 million within five years.
2022
It is planned to sign the second long-term cooperation agreement
- Led by Academician Wang Guangji of China Pharmaceutical University, and Vice President Hao Haiping as the secretary-general, the first domestic collaborative innovation alliance of pharmaceutical products, medical research and enterprise "Ginkgo Leaf Dropping Pill Medical Research and Enterprise Collaborative Innovation Alliance" was established, which is the research and development direction of the core varieties of the enterprise. put the direction.
- Signed "Research on the Mechanism of Ginkgo Leaf Dropping Pills in Preventing and Treating Ischemic Stroke", "Study on the Interaction between Ginkgo Leaf Dropping Pills and Statins", "Research on the Influence and Mechanism of Ginkgo Leaf Dropping Pills on PCSK9 Expression in Vitro and In Vitro", "Research on Elucidation of Main Active Components Group and Quality Standard Improvement of Ginkgo Leaf Dropping Pills", "Research on Tongzhi Ye Drops Registered in the European Union", "Huperzine A Injection in the Prevention and Treatment of Brain Injury-related Cognitive Impairment by PK-PD Combination" "Research" and other contract systems to carry out the secondary development research of Ginkgo biloba dropping pills and Huperzine A injection.
Achieve results
Train more than 10 masters, doctors and postdoctoral fellows
1
SCI published
1
Chinese core
post
2
apply for patent
Zhejiang University | Jointly build a joint research center
Cooperation time
July 2015 - present
Project Description
November 2016
A cooperation agreement was signed to jointly build the“Zhejiang University-Wanbangde Chinese Medicine Modernization Joint Research Center”, and the research center has a total capital scale of more than 10 million within five years. Overcompleted.
2017
Together with the School of Pharmacy of Zhejiang University, the“School of Pharmacy of Zhejiang University - Wanbangde Pharmaceutical Group Co., Ltd. Professional Degree Graduate Practice Base”was established.
December 2018-December 2019
As a sponsor, Wepon sponsored a postdoctoral fellow from Zhejiang University to enter the University of Geneva to complete his study abroad.
December 2021
Signed a cooperation agreement to jointly build the“Zhejiang University School of Pharmacy-Wanbangde Joint Research Center”,and the research center has a total capital scale of more than 6 million within three years.
Achieve results
Train more than 10 masters, doctors and postdoctoral fellows
7SCI publications 1Chinese core publication 2patents successfully introduced
Led by Wanbangde Pharmaceutical Group and the professor of Zhejiang University as the project leader, it was approved as a key R&D project in Zhejiang Province in 2018. The project has been completed and accepted, and it is planned to apply for provincial and ministerial awards.
University of Sydney | Scholarships for Chinese students to study Ph.D.
Cooperation time
August 2018 - present
Project Description
The agreement stipulates that Wanbond Pharmaceutical Group will sponsor scholarships, and provide scholarships for research masters or PhDs at the University of Sydney through the "Wanbond-Sydney University Graduate Scholarship" for research and evaluation of the effects of Ginkgo biloba dropping pills and other products on retinal degenerative diseases. Impact.
August 2018
Signed the first scholarship agreement (2019.1.1-2019.12.31) and strategic cooperation agreement
March 2020
Sign the second scholarship agreement (2020.1.1-2021.12.31)
January 2022
Achieve results
1
Train doctoral students
3
SCI published
1
Received SCI
Copyright 2016 © wanbang.com.cn All Rights Reserved.
Internet drug information service qualification certificate :(zhejiang) - non-operating -2023-0143 Powered by 300.cn
